First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide

Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma‐Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie‐Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, K. Rajender Reddy – 20 April 2022 – Real‐world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real‐world outcomes with other first‐line regimens for chronic hepatitis B (CHB). We enrolled patients with CHB from 10 centers retrospectively and followed them for 36 months prospectively.

Intraoperative intracardiac thrombus in liver transplantation: A 9‐year retrospective review focusing on treatment and outcomes

Erica Fagelman, Ryan Wang, Amanda Tomlinson, Diana Romano, Nicolette Schlichting, Jeron Zerillo, Samuel DeMaria,, Natalie K. Smith – 20 April 2022 – This study characterizes incidence and outcomes surrounding intracardiac thrombosis (ICT) during liver transplantation over 9 years at a single center before and after the routine use of transesophageal echocardiography (TEE). Adult liver transplantation patients from 2011 to 2020 were divided into eras based on routine TEE use. ICTs were identified by querying anesthetic records for search terms.

Subscribe to